Last reviewed · How we verify
MEPIVACAINE HYDROCHLORIDE
MEPIVACAINE HYDROCHLORIDE is a drug. It is currently FDA-approved (first approved 1960) for Local anesthesia for dental procedures.
Mepivacaine Hydrochloride is a marketed local anesthetic primarily used for dental procedures. Its key strength lies in its established use and safety profile, supported by a key composition patent expiring in 2028. The primary risk is the potential increase in competition as the patent approaches expiration.
At a glance
| Generic name | MEPIVACAINE HYDROCHLORIDE |
|---|---|
| Modality | Small molecule |
| Phase | FDA-approved |
| First approval | 1960 |
Approved indications
- Local anesthesia for dental procedures
Common side effects
- Nervousness
- Dizziness
- Blurred vision
- Tremors
- Drowsiness
- Sweating
- Feeling of faintness
- Cutaneous lesions
- Urticaria
- Edema
- Localized puffiness and swelling
Serious adverse events
- Persistent paresthesias of lips, tongue, and oral tissues
- Convulsions
- Unconsciousness
- Respiratory arrest
- Cerebral hypoxia
- Seizure
- Cardiovascular catastrophe
- Anaphylactoid reactions
Drug interactions
- tricyclic antidepressants or monoamine oxidase inhibitors
- ergot-type oxytocic drugs
- Phenothiazines and butyrophenones
- potent inhalation anesthetics
- drugs associated with methemoglobinemia
Key clinical trials
- Femoral Peri-arterial Local Anesthetic Injection Via Peri-arterial Perineural Catheter Reverses Tourniquet Associated Ischemic Hypertension (PHASE4)
- Discomfort Following Oral Biopsy Comparing Laser and Punch Biopsy (NA)
- Stellate Ganglion Block for COVID-19-Induced Olfactory Dysfunction (PHASE1, PHASE2)
- Comparing Spinal Anesthesia With 1% Chloroprocaine Versus 1% Mepivacaine in Patients Undergoing Outpatient Primary Total Knee Arthroplasty (PHASE4)
- Oct Angiography Changes After Local Anesthesia in Cataract Surgery (NA)
- PENG Block + LIA For Endoprosthesis Surgery With Anterior Approach (NA)
- A Randomized Controlled Trial Evaluating Whether Pre-operative Trinase Reduces Post-operative Pain in Patients With Symptomatic Irreversible Pulpitis Compared to Placebo, Using VAS Scores and Analgesic Intake Over 48 Hours. (NA)
- Platelet-Rich Plasma Versus Home-Based Exercise for Partial-Thickness Supraspinatus Tears (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MEPIVACAINE HYDROCHLORIDE CI brief — competitive landscape report
- MEPIVACAINE HYDROCHLORIDE updates RSS · CI watch RSS